Arkema Licenses PEKK Technology to SEQENS for Medical Implants

25 June 2024

Key highlights

Arkema grants SEQENS an exclusive license to manufacture PEKK for long-term medical implants.
The partnership has been ongoing for 15 years, focusing on PEKK technology and polymer production.
SEQENS will distribute IMPEKK materials globally through partners, including 3D printing companies.

Exclusive License Agreement

Arkema has granted SEQENS an exclusive technology license to manufacture PEKK for long-term medical implantable applications. This agreement marks a significant step in their 15-year collaboration, combining Arkema's expertise in PEKK technology with SEQENS' proficiency in polymer production for the pharmaceutical and life sciences markets.

PEKK Applications

PEKK, a high-performance polymer used in demanding markets like aerospace, is commercialized by Arkema under the Kepstan® trademark. SEQENS has developed IMPEKK materials specifically for long-term medical implantable applications, which will be distributed globally through a network of partners, including manufacturers and 3D printing companies.

Commitment to Innovation

SEQENS is committed to delivering top-tier solutions, leveraging its expertise in complex chemistry and polymer synthesis. Projects are already underway in Europe, the USA, and Asia, highlighting the global reach and impact of this partnership.

Source: Seqens